Cargisema (peptidedosingprotocols.com)

approvedv1

metabolic support · approved by martin@gettetonlabs.com

Provider-only template. Not patient-visible. Dosing is source-attributed or a justified provider override. Approval requires safety + monitoring summaries; high/critical safety rules require acknowledgment.

How it works

CagriSema combines cagrilintide and semaglutide to target overlapping signals in appetite regulation from the gut, pancreas, and brain. Cagrilintide is a long-acting amylin analogue that acts as a dual amylin and calcitonin receptor agonist (DACRA). Amylin is co-secreted with insulin after meals, enhancing meal-stop satiety, slowing gastric emptying, and suppressing post-meal glucagon. The Phase 1b development paper reported a half-life of approximately 159–195 hours, supporting its once-weekly dosing.

Semaglutide, a GLP-1 receptor agonist, is already FDA-approved for chronic weight management and type 2 diabetes. It reduces appetite, slows gastric emptying, and improves glycemic control through glucose-dependent insulin secretion. The combination of cagrilintide and semaglutide is rationalized by their engagement of different receptor families while overlapping on pathways related to satiety and gastric emptying.

In the REDEFINE 1 trial, the combination of CagriSema resulted in a larger average weight loss of 20.4% compared to 14.9% with semaglutide alone and 11.5% with cagrilintide alone, indicating that the two pathways are additive rather than redundant in humans. This evidence supports the efficacy of the combination in promoting weight loss and managing appetite effectively. [Source: Peptide Dosing Protocols]

Plain language: CagriSema works by combining two compounds that target different pathways in the body to help control appetite and promote weight loss.

Who should avoid it

Individuals with a history of severe gastrointestinal disorders, pancreatitis, or those who are pregnant or breastfeeding should avoid this stack. Additionally, caution is advised for those with a history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. [Source: Peptide Dosing Protocols]

Plain language: People with serious stomach problems or who are pregnant should not use this treatment.

💉 Dosing schedule

All component dosing in one place — verbatim from source or a justified provider override. Not a recommendation. Edit per component below.

Component	Dose	Route	Frequency	Duration	Cycle	Source
—primary	2.4 mg	Subcutaneous	Once weekly	12–24 weeks	12–24 weeks	Provider override
	Timing: Same day each week · Reconstitution: Pre-blended vial: add BAC water per vial spec; separate vials: reconstitute each independently.
—support	2.4 mg	Subcutaneous	Once weekly	12–24 weeks	12–24 weeks	Provider override
	Timing: Same day each week · Reconstitution: Pre-blended vial: add BAC water per vial spec; separate vials: reconstitute each independently.

Template details

CagriSema's tolerability profile is primarily characterized by gastrointestinal events, which are consistent with the GLP-1 receptor agonist class and amylin pathway literature. In the REDEFINE 1 trial involving adults with overweight or obesity without diabetes, gastrointestinal adverse events were reported in 79.6% of CagriSema participants compared to 39.9% on placebo. Specific event rates included nausea (55% vs 12.6%), constipation (30.7% vs 11.6%), and vomiting (26.1% vs 4.1%). Discontinuation due to adverse events was 5.9% on CagriSema versus 3.5% on placebo.

In the REDEFINE 2 trial involving adults with type 2 diabetes, gastrointestinal events were reported in 72.5% of CagriSema participants compared to 34.4% on placebo, with discontinuation due to adverse events at 8.4% on CagriSema versus 3% on placebo. The pattern of nausea, vomiting, and diarrhea peaked during dose escalation and tapered during maintenance, while constipation remained more stable throughout the trial period. The safety profile was described as comparable to the broader GLP-1 receptor agonist class. [Source: Peptide Dosing Protocols]

Components

(no asset)primary

(no asset)support

Safety rules

Monitoring requirements

Evidence links

Audit history (1)

2026-06-16 02:18:36 · approve_template by martin@gettetonlabs.com — Bulk-approved by provider (peptidedosingprotocols.com stack imports).